Pharmacogenomics of acute lymphoblastic leukemia

Current Opinion in Hematology

Volumn 13, Issue 4, 2006, Pages 260-265

  Kager, Leo ^a   Evans, William E ^b  

^a ST ANNA CHILDREN S HOSPITAL   (Austria)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Event free survival; Pharmacogenomics

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); 6 MERCAPTOPURINE DERIVATIVE; ANTILEUKEMIC AGENT; ASPARAGINASE; DAUNORUBICIN; GLYCINE HYDROXYMETHYLTRANSFERASE; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; BLOOD TOXICITY; BONE NECROSIS; BRAIN TUMOR; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG DISPOSITION; DRUG EFFECT; GENE EXPRESSION; GENE INTERACTION; GENE SEQUENCE; GENETIC ANALYSIS; GENETIC VARIABILITY; HOMOZYGOSITY; HUMAN; INFECTION; LYMPHOBLAST; OUTCOME ASSESSMENT; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; PHARMACOGENETICS; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS;

EID: 33747871816     PISSN: 10656251     EISSN: 15317048     Source Type: Journal    
DOI: 10.1097/01.moh.0000231424.46148.f9     Document Type: Review

References (49)

1. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354:166-178. A state-of-the-art review on the treatment of ALL.
2. Den Boer ML, Harms DO, Pieters R, et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with ALL. J Clin Oncol 2003; 21:3262-3268.
3. Cheok MH, Evans WE. Acute lymphoblastic leukemia: a model for pharmacogenomics of cancer therapy. Nat Rev Cancer 2006; 6:117-129. An exhaustive state-of-the-art review on pharmacogenomic studies related to the treatment of children with ALL.
4. Cheok MH, Lugthart S, Evans WE. Pharmacogenomics of acute leukemia. Annu Rev Pharmacol Toxicol 2006; 46:317-353. A comprehensive collection of data on pharmacogenomic studies in acute leukemia.
5. Aplenc R, Lange B. Pharmacogenetic determinants of outcome in acute lymphoblastic leukaemia. Br J Haematol 2004; 125:421-434.
6. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004; 429:464-468.
7. Cheng Q, Yang W, Raimondi SC, et al. Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes. Nat Genet 2005; 37:878-882. The first study to show that acquisition of additional chromosomes in leukemia cells alters the concordance between germline genotype and leukemia cell phenotype, depending on whether the acquired chromosome contains a wild-type or variant allele for the gene of interest.
8. Evans WE, McLeod HL. Pharmacogenomics: drug disposition, drug targets, and side effects. N Engl J Med 2003; 348:538-549.
9. Weinshilboum R. Inheritance and drug response. N Engl J Med 2003; 348:529-537.
10. Krajinovic M, Labuda D, Mathonnet G, et al. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood ALL. Clin Cancer Res 2002; 8:802-810.
11. Aplenc R, Glatfelter W, Han P, et al. CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia. Br J Haematol 2003; 122:240-244.
12. Rocha JC, Cheng C, Liu W, et al. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 2005; 105:4752-4758. An investigation of common germline sequence variants in pharmacologically relevant candidate genes and their relation to treatment outcome in children with ALL; providing evidence that genomic variation in the host can influence treatment outcome in children with ALL.
13. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336:225-229.
14. Stanulla M, Schaeffeler E, Flohr T, et al. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia. Jama 2005; 293:1485-1489. A clinical investigation demonstrating that TPMT genotypes were associated with early response to treatment in children with ALL.
15. Chen CL, Liu Q, Pui CH, et al. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood 1997; 89:1701-1707.
16. Anderer G, Schrappe M, Brechlin AM, et al. Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia. Pharmacogenetics 2000; 10:715-726.
17. Stanulla M, Schrappe M, Brechlin AM, et al. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study. Blood 2000; 95:1222-1228.
18. Allan JM, Wild CP, Rollinson S, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukaemia. Proc Natl Acad Sci U S A 2001; 98:11592-11597.
19. Davies SM, Bhatia S, Ross JA, et al. Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. Blood 2002; 100:67-71.
20. Meissner B, Stanulla M, Ludwig WD, et al. The GSTT1 deletion polymorphism is associated with initial response to glucocorticoids in childhood acute lymphoblastic leukemia. Leukemia 2004; 18:1920-1923.
21. Krajinovic M, Lemieux-Blanchard E, Chiasson S, et al. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukaemia. Pharmacogenomics J 2004; 4:66-72.
22. Aplenc R, Thompson J, Han P, et al. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 2005; 65:2482-2487. This large Children's Cancer Group study of MTHFR genotypes in ALL provides evidence that the MTHFR C677T polymorphism is a common genomic variant conferring a moderate relative risk and a high attributable risk for relapse in pediatric ALL patients.
23. de Jonge R, Hooijberg JH, van Zelst BD, et al. Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood 2005; 106:717-720. A clinical investigation that identified sequence variants in certain folate pathway genes to be related with in-vitro sensitivity of ALL cells to methotrexate.
24. Krajinovic M, Costea I, Chiasson S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 2002; 359:1033-1034.
25. Lauten M, Asgedom G, Welte K, et al. Thymidylate synthase gene polymorphism and its association with relapse in childhood B-cell precursor acute lymphoblastic leukemia. Haematologica 2003; 88:353-354.
26. Krajinovic M, Costea I, Primeau M, et al. Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis. Pharmacogenomics J 2005; 5:374-380. This study confirmed previous reports that TYMS 3R homozygous ALL patients have lower event-free survival probability, and provides evidence that homozygosity for another sequence variant in TYMS (6 bp) appeared to reduce the event-predisposing effect of the 3R variant.
27. Mehta PA, Davies SM. Pharmacogenetics of acute lymphoblastic leukemia. Curr Opin Hematol 2004; 11:434-438.
28. Elion GB. The purine path to chemotherapy. Science 1989; 244:41-47.
29. Krynetski E, Evans WE. Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 2003; 22:7403-7413.
30. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91:2001-2008.
31. Relling MV, Yanishevski Y, Nemec J, et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998; 12:346-352.
32. Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999; 354:34-39.
33. Relling MV, Pui CH, Cheng C, et al. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 2006; 107:843-844.
34. Zaza G, Cheok M, Yang W, et al. Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment. Blood 2005; 106:1778-1785. This investigation identified genomic factors that affect in-vivo accumulation of thioguanine nucleotides in ALL cells, and validated some of the relevant findings by in-vitro studies.
35. Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo: a rationale for high-dose methotrexate. J Clin Invest 1996; 97:73-80.
36. Zhao R, Goldman ID. Resistance to antifolates. Oncogene 2003; 22:7431-7457.
37. Krajinovic M, Moghrabi A. Pharmacogenetics of methotrexate. Pharmacogenomics 2004; 5:819-834.
38. Kager L, Cheok M, Yang W, et al. Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics. J Clin Invest 2005; 115:110-117. The first study to document that folate pathway gene expression differs among ALL subtypes and is related to the cellular accumulation of active methotrexate metabolites; pointing to ALL subtype-specific strategies to overcome altered methotrexate disposition in ALL cells.
39. Holleman A, Cheok MH, den Boer ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004; 351:533-542.
40. Lugthart S, Cheok MH, den Boer ML, et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell 2005; 7:375-386. This study identified genes whose expression patterns were associated with drug cross resistance and long-term outcome in ALL. Moreover, a subset of patients was identified with a markedly poor outcome, and a phenotype of discordant sensitivity to asparaginase and vincristine.
41. Cario G, Stanulla M, Fine BM, et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood 2005; 105:821-826. This investigation identified gene expression patterns in diagnostic ALL samples, predictive for in-vivo drug response (MRD).
42. Relling MV, Yang W, Das S, et al. Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia. J Clin Oncol 2004; 22:3930-3936.
43. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1:133-143.
44. Bogni A, Cheng C, Liu W, et al. Genome-wide approach to identify risk factors for therapy-related myeloid leukemia. Leukemia 2006; 20:239-246. This study illustrates that germline driven gene expression across different tissues may predict therapy-related myeloid leukemia.
45. Edick MJ, Cheng C, Yang W, et al. Lymphoid gene expression as a predictor of risk of secondary brain tumors. Genes Chromosomes Cancer 2005; 42:107-116. Another study which illustrates that germline driven gene expression across different tissues may predict therapy-related secondary malignancy.
46. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30:41-47.
47. Brown P, Levis M, Shurtleff S, et al. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 2005; 105:812-820. This study shows that the FLIT3 inhibitor CEP-701 inhibits cell growth in ALL cell lines and ALL cells that overexpress FLT3.
48. Stam RW, den Boer ML, Schneider P, et al. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 2005; 106:2484-2490. This investigation provides evidence that FLT3 inhibitor induced apoptosis in infant MLL-positive ALL cells is unlikely to be a consequence of FLT3 inhibition alone but may involve inhibition of multiple other kinases.
49. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349:1157-1167.